Biotech Archives - Page 656 of 733

1 minute read

This Hepatitis Stock Has ‘Multiple Paths To Value Creation,’ Expects To Double, Bullish Analyst Predicts

September 14, 2:11 PM

SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ:VIR) with an Outperform rating and a price target of $40, with an investment…

VIR

1 minute read

US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing

By Vandana Singh

September 14, 2:07 PM

As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…

ABBV

1 minute read

Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims

By Vandana Singh

September 14, 2:05 PM

A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.

NVS

2 minute read

Ligand Pharmaceuticals Licensor Of Sermonix Pharmaceuticals Shares Details Of Durable Complete Clinical Response In A Metastatic ER+/HER2- Breast Cancer Patient With An ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Ba…

By Benzinga Newsdesk

September 14, 11:28 AM

Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah

LGND

1 minute read

Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise

By Vandana Singh

September 14, 10:27 AM

POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds…

AKRO

1 minute read

FDA Grants Orphan Drug Status To Centessa’s Hemophilia B Candidate

By Ragothaman Srinivasan

September 14, 10:07 AM

Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.

CNTA